Optimizing biopsy decisions in PI-RADS 3 lesions: cross-institutional validation of a local clinical risk model
Authors:
- Dominik DeniffelDDDominik Deniffel
- Nathan PerlisNPNathan Perlis
- Sangeet GhaiSGSangeet Ghai
- Emmanuel Salinas-MirandaESEmmanuel Salinas-Miranda
- Khashayar NamdarKNKhashayar Namdar
- Laurence H. KlotzLKLaurence H. Klotz
- Alexandre ZlottaAZAlexandre Zlotta
- Antonio FinelliAFAntonio Finelli
- Masoom A. HaiderMHMasoom A. Haider
- 28 April 2025
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-9
Abstract
Purpose To compare a locally developed risk model based on clinical parameters with previously published models and strategies to reduce MRI-targeted biopsies of indeterminate PI-RADS 3 lesions without missing clinically significant prostate cancer (csPCa) (ISUP ≥ grade 2). Methods Retrospective, two-center study including 278 patients without prior PCa who underwent multiparametric MRI and MRI-targeted biopsy. For robust parameter estimation, a risk model based on clinical parameters was developed in a high-prevalence cohort (institution 1; n = 202; PI-RADS 3–5) and recalibrated to PI-RADS 3 subgroup (n = 115). The validation cohort (institution 2, same metropolitan area) consisted of 76 men with PI-RADS 3 index lesions. Model performance was compared to previously suggested strategies and risk models using decision curve analysis. Results The local risk model provided the highest net benefit across all clinically relevant risk thresholds in the validation cohort. At a 10% risk threshold, the model could safely avoid biopsies in 547 per 1,000 men with PI-RADS 3 index lesions without missing csPCa, outperforming other strategies in number of biopsies avoided: normalized ADC (223), PSA density (210), MRI-ERSPC risk calculator (164), lesion volume (55) and the Radtke risk model (0). At low risk thresholds < 10% both normalized ADC (0.81) and PSA density (0.08 ng/ml/ml) were clinically useful. Conclusion A locally fit risk model based on clinical parameters could safely reduce unnecessary biopsies in men with PI-RADS 3 index lesions, with normalized ADC and PSA density providing useful and easy-to-use alternatives.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG) fellowship
- Ontario Institute for Cancer Research
This publication has 27 references indexed in Scilit:
- PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI‐RADS 3 LesionsThe Prostate, 2024
- Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS ScoreEuropean Urology Focus, 2023
- Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsyEuropean Journal of Radiology, 2023
- Prediction of Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging Lesions: A High-volume International Multicenter StudyEuropean Urology Focus, 2023
- The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate BiopsiesEuropean Urology Focus, 2021
- Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Focus, 2020
- Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1European Radiology, 2020
- Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic centerEuropean Journal of Radiology, 2019
- Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detectionEuropean Journal of Radiology, 2017
- PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2European Urology, 2016